Biotech Outsourcing Strategies Basel 2025

BOS Basel 2025 Programme

BOS Basel 2025's scope is primarily development-stage CMC outsourcing for both Small Molecules and Biologics, as well as covering Novel Therapeutic Entities.

We have a single-track programme consisting of high-quality presentations and drawing from the diverse organisation types in the community including multinational pharmaceutical companies, speciality pharma, SME biotech, CRO/CMO and Consultants. Our programme consists of the following modules:

Outsourcing Business Process
Exploring strategies and processes driving sourcing and procurement of R&D services

Technical Operations
Exploring the technical elements of outsourcing discovery R&D, Drug Substance Outsourcing, Analytical Development Outsourcing, Drug Product Outsourcing for Biologics and Small Molecules.

Outsourcing Case Studies
Building on the Technical Operations sessions, demonstrating outsourcing approaches to real life scenarios.

Share this page

Day 1 - 11th June 2025

Time	BOS Basel Programme
08:00 - 09:00	Registration and Partnering (10 min Partnering Slots)
09:00 - 10:30	Outsourcing Process and Strategies Chair: Dr Frederik Barfoed Beck, Senior Outsourcing Manager, Zealand Pharma
09:00 - 09:30	Considerations for Developing and Executing a CMC Outsourcing Strategy Mr Julius Simonelli, Executive Director, Strategic Outsourcing - Technical Research & Development, Novartis About the speaker Full Speaker profile
09:00 - 09:30	Sourcing and Procurement Toolkit for the Biotech Start Up Mr Alexander Burkard, Senior Manager, Manufacturing & Outsourcing, Immunocore Ltd. About the speaker Full Speaker profile
10:00 - 10:15	Revolutionizing Pharma Outsourcing with AI: How Procurement CoPilot™ Accelerates Research Dr Frederik Deroose, VP Chemistry and CMC, Scientist.com About the speaker Full Speaker profile
10:15 - 10:30	Speaker to be Confirmed
10:30 - 11:00	Coffee and Partnering
11:00 - 12:00	Outsourcing Case Studies Chair: Dr Miranda de Jager, Owner/Principal Consultant CMC, M3 Pharma Consultancy
11:00 - 11:20	CDMO Sourcing for Clinical Stage Biotech: Strategic Dilemmas Michel David, VP CMC, Manufacturing and Supply Chain, NOEMA Pharma AG About the speaker With over 25 years of experience in Pharmaceutical Manufacturing and Development, Michel leverages his broad cross functional experience covering the End-to-End supply chain, taking molecules to market, as well as managing partnership with external providers. Prior to joining NOEMA, Michel held several responsibilities in Roche Pharma, including; Leading a global small molecules Drug Product Manufacturing Site where he launched new products, Developing and implementing global manufacturing network strategies, Setting up external manufacturing operations and driving Operational Excellence. Michel started his career at Aventis as a Chemical process engineer in Pharma Development. Michel is a strategic thinker, with business acumen and a passion for driving execution and delivering safe and compliant drugs to the patients. Michel holds a MSc. in Chemistry, a Chemical Engineering degree from ENSCP, Paris and an MBA from INSEAD. Full Speaker profile
11:20 - 11:40	Overcoming Challenges in Transferring a Sterile Biologics Drug Product to a CDMO Mr Olaf Wegener, Head r&d, Siegfried AG About the speaker Full Speaker profile
11:40 - 12:00	Considerations for Selecting a Data Platform to Accelerate Research Dr Lotti Frauchiger, Head CMC, Molecular Partners About the speaker Lotti Frauchiger joined Molecular Partners AG (Zurich, Switzerland) as Head of CMC in 2022. She is a trained pharmacist (ETH Zurich) with a Ph.D. in Chemistry (Rutgers University, NJ, USA). In her career of over 20 years in the chemical and biotech industries she held roles of increasing responsibilities in development, CDMO management and manufacturing of small and large molecules. Additionally, Lotti co-led a research data platform and company culture initiatives. Full Speaker profile
12:00 - 13:30	Lunch and Partnering
13:30 - 15:30	Technical Operations Outsourcing Chair: Dr Reinhard Karge, Executive President, RCJ unlimited - Karge consulting
13:30 - 14:00	Discovery and process development of the new Antibiotic Zosurabalpin Dr Patrizio Mattei, Distinguished Scientist, Medicinal Chemistry, F. Hoffmann-La Roche Ltd. Dr Ernesto Santandrea, Senior Principal Scientist, F. Hoffmann - La Roche About the speaker Patrizio Mattei is an Expert Scientist, Medicinal Chemistry at the Roche Innovation Center Basel. Before joining Roche in 1999, he earned a Doctor of Sciences degree from the ETH Zürich and was a postdoctoral research fellow at The Scripps Research Institute in La Jolla, California. Full Speaker profile About the speaker Ernesto Santandrea has been acting as Senior Principal Scientist in Process Chemistry and Catalysis at F. Hoffmann-La Roche (Basel) for the past four years. He has over 14 years experience in the development of chemical manufacturing processes of active pharmaceutical ingredients, mainly in the late stage of development, and their transfer to commercial manufacturing scale. Full Speaker profile
14:00 - 14:30	Presentation to be Confirmed
14:30 - 15:00	Building Robust CDMO Selection Strategies for Biologics Development Mr Jay Howlett, Director, External Operations, Vir Biotechnology About the speaker Jay Howlett is the Director of External Operations for the mAb platform at Vir Biotechnology in San Francisco, CA. He has worked in the biotechnology industry for over 20 years in the small biotech, innovator company and contract manufacturing spaces. Previous to Vir, Jay spent 15 years at Genentech/Roche where for 10 years he worked on commercial product transfers (DS, DP and packaging) to support both internal and external needs world-wide and then 5 years in the development space within external manufacturing supporting CMC teams. His contract manufacturing career started at DSM Biologics in Montreal, Canada for early and late stage DS biologics manufacturing. Jay holds an undergraduate degree in chemical engineering from the University of Waterloo (ON, Canada) and a Master of Science in Biology/Biotechnology from Carleton University (ON, Canada). Full Speaker profile
15:00 - 15:15	From Spray Drying to Hot Melt Extrusion: Innovative Techniques to Unlock the Potential of Amorphous Solid Dispersions and Improve API Bioavailability: Laure Descamps, Formulation Development Scientist, Ardena
15:15 - 15:30	From Preclinical to Clinical: Key Steps for a Successful Transition Dr Oliver Okle, Product and Service Manager, Vetter Pharma Fertigung GmbH & Co. KG About the speaker Oliver joined Vetter in 2021 as a Product Manager, supporting the development service for early and late clinical filling and analytics team with his extensive operational and analytical experience. Prior to joining Vetter, he honed his product and project management skills in various manufacturing, industrial and service companies in Germany, focusing on medical devices, R&D and pharmaceuticals. Oliver holds a Master of Science in Molecular- and Microbiology from the University of Konstanz, Germany, where he also earned his PhD in Human and Environmental Toxicology. Full Speaker profile
15:30 - 16:00	Coffee and Partnering
16:00 - 17:00	Outsourcing Case Studies Chair: Dr Rudolf Hausmann, Partner/Consultant, Viopas Venture Consulting
16:00 - 16:20	Streamlined and Cost-Efficient Drug Product Development from Lab to Market with Mesoporous Magnesium Carbonate (MMC) Dr Marc Willuhn, Managing Director; Director Process Development, Willuhn Consulting; Disruptive Pharma About the speaker Marc is a senior CMC consultant with a broad and varied experience, covering projects from preclinical to commercial, from small molecules to biologics and ATMP, in various dosage forms. He mostly supports startup biotech companies as Head of CMC, developing strategies, identifying and engaging with external partners and CDMOs, executing projects to ensure drug supply and regulatory approval. Marc is attending BOS Basel 2025 in his role as Director Process Development at Disruptive Pharma, an innovative clinical stage biotech and drug delivery company leveraging its innovative mesoporous magnesium carbonate (MMC) technology to enable amorphous drug formulations. Full Speaker profile
16:20 - 16:40	From Vials to Vessels: Discovery and Development in the Salt / Cocrystal Continuum - Demonstrating Process Control at Scale Incorporating Particle Engineering Strategies Dr Ruth Lunt, Senior Scientist, Veranova About the speaker Ruth completed her PhD at the University of Bath as part of CMAC where she worked on the preferential crystallization of metastable forms using both batch and continuous crystallization techniques. Since joining Veranova in 2019, Ruth has become a key member of the crystallization development team, working on a range of crystallization projects and aiding the continual development of this offering. Full Speaker profile
16:40 - 17:00	In-house Manufacture or External Sourcing of Gene Editing Reagents to support the Growing Cell and Gene Therapy Business Dr Ulrich Rümenapp, Senior Program Lead, Bayer AG About the speaker Dr. Rümenapp is based in Wuppertal, Germany and working within the Product Supply Biotech organization of Bayer AG, where he is responsible for the transfer of Bayer’s pipeline candidates (antibodies and antibody-drug-conjugates) to external manufacturing partners and regulatory submission and launch preparations. Prior to working in Development, Dr. Rümenapp was Head of Biotech Projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances and drug products and interdisciplinary project management with the goal to ensure market supply. Before it was acquired by Bayer, Dr. Rümenapp hold a similar position at Schering AG, and before that, he worked in the Production & Logistics department of Schering, where he was responsible for production aspects of in- and out-licensing deals, due diligences, and product acquisitions of small molecule products and biologics. Dr. Rümenapp studied chemistry and holds a Ph.D. in biosciences. He worked several years in academic research in the field of signal transduction and as an assistant teacher in the field of general pharmacology. Today, Dr. Rümenapp area of expertise is the set-up and management of external relationships for the development and supply of bio-pharmaceutical products. He has more than 20 years of experience in the bio-pharmaceutical industry.To correspond with Dr. Rümenapp, please contact him at [email protected]. Full Speaker profile
17:00 - 19:00	Drinks Reception

Time	BOS Basel Programme
08:00 - 09:00	Refreshments and Partnering
09:00 - 11:00	Technical Operations Outsourcing
09:00 - 09:30	Early Phase to Full Scale Manufacturing. An Overview of Biocatalysis at Novartis Pharma Florian Kleinbeck, Director of Biocatalysis, Novartis Pharma AG About the speaker Florian Kleinbeck is Director of Biocatalysis at Novartis in Basel (Switzerland). Following a PhD in natural product synthesis at ETH Zurich (Switzerland) and a postdoc in asymmetric catalysis at UC Berkeley(USA), he joined Novartis in Chemical & Analytical Development. Since his start, he contributed as process chemist and project leader to late phase development projects and transfers into production for both small molecule and oligonucleotide projects. In addition, he extensively supported technical lifecycle management activities of established brands. In early 2024, he took on the role as team lead of the Biocatalysis Team in Chemical & Analytical Development at Novartis. Full Speaker profile
09:30 - 10:00	How the Biosecure Act ,and Wider Geopolitical Trends, are Shaping Manufacturing Sourcing Strategies Dr Carl Hitscherich, Head of External Supply, Alnylam About the speaker Full Speaker profile
10:00 - 10:30	Antibody Drug Conjugates: Panorama, perspectives and manufacturing challenges Dr Olivier Cochet, Head Pharmaceutical Development, Debiopharm International SA About the speaker Debiopharm International is a highly focused company that develops drugs and therapies with a view to bringing novel biopharmaceuticals to market. The business strategy is to create partnerships for the in-licensing of biologics and small molecules from biotechnology and pharmaceutical companies as well as academic institutions worldwide. Lead the Pharmaceutical Development department to ensure the development and manufacturing of products tailored to the needs of patients Full Speaker profile
10:30 - 10:45	Gold Sponsor Presentation - Neuland Labs
10:45 - 11:00	Electron Diffraction for Solid State Investigations Dr Pierric MARCHAND, Founder & General Manager, HOLODIAG About the speaker I am French, born in Normandy in 1977. I hold a master's degree in organic chemistry (1999) and defended my PhD thesis in physics, thermodynamics of heterogeneous equilibria applied to crystallization of small molecules, in 2004. Under contract with a dozen of pharma company during this period, I founded Holodiag right after my PhD. And as everyone knows (I hope so !) Holodiag is a CRO dedicated to solid state and crystallization of small molecules since 2006. Full Speaker profile
11:00 - 11:30	Refreshments and Partnering
11:30 - 12:30	Outsourcing Case Studies Chair: Dr Harald Hufsky, MBA, Sr. Pharma Consultant, Dr. Harald Hufsky Pharma Consulting
11:30 - 11:45	Large-Scale Synthesis of LPA1-Receptor Antagonist ACT-1016-0707 Mrs Florence Masse, Senior Research Associate, Chemistry Process R&D, Idorsia Pharmaceuticals Ltd. About the speaker Full Speaker profile
11:45 - 12:00	Gold Sponsor Presentation - Axplora
12:00 - 12:15	Case Study for CDMO Selection : Case Study for a Phase 1 Recombinant Protein Candidate Yogeshwar Bachhav, Consultant:, AiCuris Anti-infective Cures AG About the speaker Yogeshwar Bachhav is a pharmacist by training and has PhD in advanced drug-delivery systems from ICT, Mumbai (India). He has around 16 years of post-PhD experience in Europe in the field of pharmaceutical development of investigational drugs. He has contributed to the success of the clinical candidates ranging from preclinical to phase 1, 2, and 3 trials followed by commercial launch. Yogesh has worked as a Research Scientist for around four years on a collaborative project between Pantec Biosolutions AG (Lichtenstein) and University of Geneva, Switzerland. After this, he has worked as a Formulation Manager at Debiopharm Group, Lausanne, Switzerland, for around four years in the capacity of a lab head, where he successfully developed preclinical and clinical formulations for oncology indication. Currently Yogesh is working as a Associate Director (Consultant) at AiCuris Anti-infective Cures AG Germany and responsible for pharmaceutical development of investigational drugs in the domain of innovative anti-viral and anti-bacterial drugs. Yogesh’s expertise in the field of advanced drug-delivery system comprises pre-formulation, formulation development of small molecules and/or peptides for oral, dermal, and parenteral applications. Also, he has exposure to in-house development and outsourcing these novel dosage forms. Besides several publications in the targeted formulation field, Yogesh is a well-known expert with over 30 conference proceedings and has been named Wiley-VCH in the same book series titled Innovative Dosage Forms: Design and Development at Early Stage. He is also serving as visiting faculty at reputed Pharmacy Schools in India. Full Speaker profile
12:15 - 12:30	To Be Confirmed
12:30 - 14:00	Lunch and Partnering
14:00 - 15:00	Panel Discussion - Navigating Geopolitical Headwinds in Pharmaceutical Outsourcing Dr Tarita Qveflander, Head of Strategic Sourcing and Direct Procurement, Swedish Orphan Biovitrum AB Dr Carl Hitscherich, Head of External Supply, Alnylam About the speakers About the speaker Tarita Qveflander is the Head of Strategic Sourcing and Direct Procurement at Sobi – Swedish Orphan Biovitrum AB. Tarita has 18+ years of pharmaceutical operations, supply chain, and procurement experience. She also has extensive knowledge of global API/drug substance, drug product, and finished goods supply chain, including hands-on technical expertise and a deep understanding of quality and GMP regulations. Full Speaker profile Carl Hitscherich About the speaker Full Speaker profile
15:00 - 16:00	Conference Close & Drinks Reception